Exploring Combinations of Tisotumab Vedotin in Cervical Cancer

Brian Slomovitz, MD, MS, FACOG, director of Gynecologic Oncology at Mount Sinai Medical Center in Miami Beach, Florida and a Uterine Cancer Clinical Trial lead within the Gynecologic Oncology Group (GOG) Foundation, discusses the potential use of tisotumab vedotin-tftv (​​Tivdak) in combinations for the treatment of patients with second- or third-line recurrent or metastatic cervical cancer.

In this video, Slomovitz discusses tisotumab vedotin, a treatment for recurrent or metastatic cervical cancer. Tisotumab vedotin is currently being studied in the phase 3 innovaTV 301/ENGOT-cx12/GOG-3057 trial (NCT04697628) where it is being compared with investigator’s choice of chemotherapy when utilized in the second- or third-line for patients with recurrent or metastatic cervical cancer with disease progression on doublet chemotherapy.

While it is currently approved by the FDA for use as a single agent, research on combinations with tisotumab vedotin is ongoing. Earlier trials are exploring combining tisotumab vedotin with carboplatin, pembrolizumab (Keytruda), and other drugs. The promising results of these studies suggest that future treatment directions might involve combining tisotumab vedotin with other therapies. However, for now, it remains a valuable option, particularly for patients whose cancer has recurred after other treatments.

Transcription:

0:09 | So as far as combinations go, we are exploring them. There are earlier trials looking to [combine] tisotumab vedotin with a series of combinations, including carboplatin with pembrolizumab and other agents. At this point, I think the results of this study will make us further explore to see if some of the future directions will include combination therapy, but for now, based on the current landscape, it will definitely be a good treatment option in the second-, or third-line [for] patients, these patients who recur.